Sanofi and GSK Report Results of its COVID-19 Vaccine in a P-II Study Across All Adult Age Groups

 Sanofi and GSK Report Results of its COVID-19 Vaccine in a P-II Study Across All Adult Age Groups

Sanofi and GSK Report Results of its COVID-19 Vaccine in a P-II Study Across All Adult Age Groups

Shots:

  • The vaccine has achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a P-II study
  • The results showed 95%-100% seroconversion following the second injection in all age groups (18-95yrs. old) & across all doses, with acceptable tolerability & no safety concerns. The high immune response following the single dose in patients with prior infection shows strong booster potential of the vaccine
  • The companies are planning to start the P-III study in the coming weeks and are expecting the vaccine to be approved in Q4’21, following the positive P-III outcomes & regulatory reviews

Click here to­ read full press release/ article | Ref: Sanofi | Image: Medcity News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post